Abpro Holdings (ABP) announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its global collaboration partner, Celltrion, at the 2026 J.P. Morgan Healthcare Conference. “The inclusion of ABP-102 in Celltrion’s presentation at the J.P. Morgan Healthcare Conference represents a meaningful validation of the program and its potential,” said Miles Suk, Chief Executive Officer of Abpro. “JPM remains the most influential healthcare investment forum globally, and having ABP-102 highlighted by a leading global biopharmaceutical partner underscores the strength of our science, our collaboration with Celltrion, and the momentum we are building following recent IND clearance.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABP:
- FDA Clears Abpro’s Lead HER2 Cancer Drug for Phase 1
- Abpro, Celltrion announces U.S. FDA cleared IND application for ABP-102
- Abpro Holdings Submits IND Application for Cancer Drug
- Abpro Holdings submits IND application for Phase 1 trial of ABP102/CT-P72
- Abpro Holdings Granted Nasdaq Compliance Extension